Literature DB >> 3880069

Systemic absorption of topically applied ocular timolol.

T Kaila1, L Salminen, R Huupponen.   

Abstract

Symptoms and findings arising from the systemic beta blockade caused by topical ocularly applied timolol appear shortly after drug application. We studied the systemic absorption of 20 microliters of 0.5% timolol instilled unilaterally in the lower conjunctival cul-de-sac in 6 volunteers. At 3 min one subject, at 5 min three and at 8 min all but one showed measurable (greater than or equal to 215 pg/ml) timolol concentrations in the plasma. The rapid systemic absorption of topically applied ocular timolol observed in our study is consistent with the rapid appearance of the cardiovascular and pulmonary side effects reported in connection with timolol eye drop therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880069     DOI: 10.1089/jop.1985.1.79

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  5 in total

1.  Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.

Authors:  L Salminen; R Lindberg; H R Toivari; R Huupponen; T Kaila; E Iisalo
Journal:  Int Ophthalmol       Date:  1989-01       Impact factor: 2.031

Review 2.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

3.  Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients.

Authors:  M L Vuori; T Kaila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-03       Impact factor: 3.117

Review 4.  Systemic reactions to ophthalmic drug preparations.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 5.  Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Authors:  Daniel J Yoon; Ramanjot Kaur; Anthony Gallegos; Kaitlyn West; Hsinya Yang; Saul Schaefer; Catherine Tchanque-Fossuo; Sara E Dahle; R Rivkah Isseroff
Journal:  Am J Clin Dermatol       Date:  2020-11-25       Impact factor: 7.403

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.